Freenome, Inc. Net Fee Amt
Freenome, Inc. (FRNM) had Net Fee Amt of $18.39 thousand as of 2026-09-23, per its S-8 filed 2026-09-23.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-09-23
- 2026-09-23: Net Fee Amt $18.39K.
- 2026-08-18: Net Fee Amt $120.92K.
- 2026-04-28: Net Fee Amt $17.23K.
| Period end | Net Fee Amt |
|---|---|
| 2026-09-23 | $18.39K S-8 · filed 2026-09-23 |
| 2026-08-18 | $120.92K S-1 · filed 2026-08-18 |
| 2026-04-28 | $17.23K S-4 · filed 2026-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |